1227 related articles for article (PubMed ID: 16827663)
1. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
[TBL] [Abstract][Full Text] [Related]
2. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
[TBL] [Abstract][Full Text] [Related]
3. Induced fit in HIV-neutralizing antibody complexes: evidence for alternative conformations of the gp120 V3 loop and the molecular basis for broad neutralization.
Rosen O; Chill J; Sharon M; Kessler N; Mester B; Zolla-Pazner S; Anglister J
Biochemistry; 2005 May; 44(19):7250-8. PubMed ID: 15882063
[TBL] [Abstract][Full Text] [Related]
4. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 peptide vaccine candidates: selecting constrained V3 peptides with highest affinity to antibody 447-52D.
Mester B; Manor R; Mor A; Arshava B; Rosen O; Ding FX; Naider F; Anglister J
Biochemistry; 2009 Aug; 48(33):7867-77. PubMed ID: 19552398
[TBL] [Abstract][Full Text] [Related]
6. Dual specificity of a monoclonal anti-idiotypic antibody for HIV-1 neutralizing monoclonals 110.3 and 110.4 as well as the V3 loop of gp120.
Connelly RJ; Kahn M; Blake J; Haffar OK; Thomas EK
Virology; 1994 Dec; 205(2):554-7. PubMed ID: 7526543
[TBL] [Abstract][Full Text] [Related]
7. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1.
Borbe HC; Stuber G; Wagner R; Wolf H; Modrow S
J Pept Sci; 1995; 1(2):109-23. PubMed ID: 9222988
[TBL] [Abstract][Full Text] [Related]
8. Structural studies of human HIV-1 V3 antibodies.
Stanfield RL; Wilson IA
Hum Antibodies; 2005; 14(3-4):73-80. PubMed ID: 16720977
[TBL] [Abstract][Full Text] [Related]
9. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
Kang CY; Luo L; Wainberg MA; Li Y
Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
[TBL] [Abstract][Full Text] [Related]
10. Expression, purification, and isotope labeling of a gp120 V3 peptide and production of a Fab from a HIV-1 neutralizing antibody for NMR studies.
Sharon M; Görlach M; Levy R; Hayek Y; Anglister J
Protein Expr Purif; 2002 Apr; 24(3):374-83. PubMed ID: 11922753
[TBL] [Abstract][Full Text] [Related]
11. Permissive residues within the minimal epitopes of neutralizing monoclonal antibodies to the V3 loop of HIV-1.
Laisney IL; Benjamin H; Gefter M; Strosberg AD
Eur J Immunol; 1996 Jul; 26(7):1634-40. PubMed ID: 8766572
[TBL] [Abstract][Full Text] [Related]
12. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
[TBL] [Abstract][Full Text] [Related]
13. A disulfide-bound HIV-1 V3 loop sequence on the surface of human rhinovirus 14 induces neutralizing responses against HIV-1.
Zhang A; Geisler SC; Smith AD; Resnick DA; Li ML; Wang CY; Looney DJ; Wong-Staal F; Arnold E; Arnold GF
Biol Chem; 1999 Mar; 380(3):365-74. PubMed ID: 10223339
[TBL] [Abstract][Full Text] [Related]
14. Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate.
Shibata J; Yoshimura K; Honda A; Koito A; Murakami T; Matsushita S
J Virol; 2007 Apr; 81(8):3757-68. PubMed ID: 17251298
[TBL] [Abstract][Full Text] [Related]
15. Conformation of the principal neutralizing determinant of human immunodeficiency virus type 1 in complex with an anti-gp120 virus neutralizing antibody studied by two-dimensional nuclear magnetic resonance difference spectroscopy.
Zvi A; Feigelson DJ; Hayek Y; Anglister J
Biochemistry; 1997 Jul; 36(28):8619-27. PubMed ID: 9214308
[TBL] [Abstract][Full Text] [Related]
16. Affinity maturation of a high-affinity human monoclonal antibody against the third hypervariable loop of human immunodeficiency virus: use of phage display to improve affinity and broaden strain reactivity.
Thompson J; Pope T; Tung JS; Chan C; Hollis G; Mark G; Johnson KS
J Mol Biol; 1996 Feb; 256(1):77-88. PubMed ID: 8609615
[TBL] [Abstract][Full Text] [Related]
17. A universal T cell epitope-containing peptide from hepatitis B surface antigen can enhance antibody specific for HIV gp120.
Greenstein JL; Schad VC; Goodwin WH; Brauer AB; Bollinger BK; Chin RD; Kuo MC
J Immunol; 1992 Jun; 148(12):3970-7. PubMed ID: 1376346
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity comparison of a multi-antigenic peptide bearing V3 sequences of the human immunodeficiency virus type 1 with TAB9 protein in mice.
Cruz LJ; Quintana D; Iglesias E; Garcia Y; Huerta V; Garay HE; Duarte C; Reyes O
J Pept Sci; 2000 May; 6(5):217-24. PubMed ID: 10823490
[TBL] [Abstract][Full Text] [Related]
19. NMR study and comparison of the antigenic properties of a peptide recognized by two HIV-1 neutralizing antibodies.
Tsang P; Mu X; Wu G; Durda PJ
J Mol Recognit; 1997; 10(6):256-61. PubMed ID: 9770649
[TBL] [Abstract][Full Text] [Related]
20. The cross-clade neutralizing activity of a human monoclonal antibody is determined by the GPGR V3 motif of HIV type 1.
Zolla-Pazner S; Zhong P; Revesz K; Volsky B; Williams C; Nyambi P; Gorny MK
AIDS Res Hum Retroviruses; 2004 Nov; 20(11):1254-8. PubMed ID: 15588347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
